| Edward M. Kaye |
Dr. Edward M. Kaye, MD, is an Independent Director at Avidity Biosciences, Inc., a Chief Executive Officer & Director at Stoke Therapeutics, Inc., an Independent Director at Cytokinetics, Inc. and an Advisory Board Member at CureDuchenne Ventures LLC. He is on the Board of Directors at Avidity Biosciences, Inc., Stoke Therapeutics, Inc., Cytokinetics, Inc. and Massachusetts Biotechnology Council. Dr. Kaye was previously employed as an Independent Director by NeuroVia, Inc., a Group Vice President-Clinical Development by Genzyme Corp., a Chief-Biochemical Genetics by The Children's Hospital of Philadelphia, a Chief-Neurology by St. Christopher's Hospital for Children LLC, and an Associate Professor by Perelman School of Medicine. He also served on the board at Sarepta Therapeutics, Inc. He received his undergraduate degree from Loyola University New Orleans and a doctorate degree from Stritch School of Medicine. |
| Joan Wood |
Ms. Joan Wood is a Chief Human Resources Officer at Stoke Therapeutics, Inc. Ms. Wood was previously employed as a Chief Human Resources Officer & Senior VP by Karyopharm Therapeutics, Inc., a Vice President & Head-Human Resources by Sarepta Therapeutics, Inc., and a Senior Vice President-Human Resources by Genzyme Corp. She also served on the board at National Initiative for Children's Health Care Quality, Inc. and Writeboston. She received her undergraduate degree from the University of Saint Joseph and a graduate degree from Boston University. |
| Shamim Ruff |
Ms. Shamim Ruff is a Chief Regulatory Officer at Stoke Therapeutics, Inc., a Member at American Society of Clinical Oncology, Inc., a Member at American Society of Gene & Cell Therapy, a Member at Develop Innovate Advance, a Member at Regulatory Affairs Professionals Society and a Member at The Royal Society of Chemistry. Ms. Ruff was previously employed as an Independent Director by Reata Pharmaceuticals, Inc., a Chief Regulatory Affairs Officer & Senior VP by Sarepta Therapeutics, Inc., a Vice President-Regulatory Affairs by Genzyme Corp., and an Executive Director-US & Global Regulatory Affairs by Amgen, Inc. She received her undergraduate degree from the University of Leicester and a graduate degree from Loughborough University. |
| Jason Hoitt |
Mr. Jason Hoitt is a Chief Commercial Officer at Stoke Therapeutics, Inc. Mr. Hoitt was previously employed as a Chief Commercial Officer by Provention Bio, Inc., a Chief Commercial Officer by Dova Pharmaceuticals, Inc., a Vice President & Head-US Sales by Insmed, Inc., and a Head-US Sales by Sarepta Therapeutics, Inc. He received his undergraduate degree from the College of the Holy Cross (Massachusetts). |
| Barry S. Ticho |
Mr. Barry S. Ticho is a Chief Medical Officer at Stoke Therapeutics, Inc. Mr. Ticho was previously employed as a Head-Cardiovascular & Metabolic Diseases by Moderna Therapeutics Inc, a Head-External Research & Development Innovation by Pfizer Inc., a Vice President-Clinical Development by Biogen Idec, Inc., a Member by The General Hospital Corp., and a Member by Harvard Medical School. He also served on the board at Verve Therapeutics, Inc. He received his undergraduate degree from Haverford College and a doctorate degree from The University of Chicago. |
| Huw M. Nash |
Dr. Huw M. Nash is a Chief Operating & Business Officer at Stoke Therapeutics, Inc. Dr. Nash was previously employed as a Vice President-Corporate Development by Aileron Therapeutics, Inc. and a VP-External Collaborations & Founding Scientist by NeoGenesis Pharmaceuticals, Inc. He received his undergraduate degree from Harvard College and a doctorate degree from Harvard University. |
| Seth L. Harrison |
Dr. Seth L. Harrison is an Independent Non-Executive Director at Akero Therapeutics, Inc., a Chairman at Stoke Therapeutics, Inc., a Founder & Managing Partner at Apple Tree venture Managemnet Llc//vc, a Chairman at Adendra Therapeutics Ltd., a Chairman at Aethon Therapeutics, Inc., a Chairman at Braeburn Pharmaceuticals SPRL, a Chairman at Braeburn, Inc., a Chairman at Limelight Bio, Inc., a Chairman at Marengo Therapeutics, Inc., a Chairman at Nereid Therapeutics, Inc., a Chief Executive Officer at Apple Tree Life Sciences, Inc. and a Treasurer & Director at Syntimmune, Inc. He is on the Board of Directors at Akero Therapeutics, Inc., Aulos Bioscience, Inc., Apertor Pharmaceuticals, Inc., Ascidian Therapeutics, Inc., Gala Therapeutics, Inc., Galavant Therapeutics, Inc., Galaxy Medical, Inc., Galvanize Therapeutics, Inc., Harrison Atelier Foundation, Initial Therapeutics Inc, Intergalactic Therapeutics, Inc., Marlinspike Therapeutics, Inc., Nine Square Therapeutics, Inc., Replicate Bioscience, Inc., Tortoise Foundation and Syntimmune, Inc. Dr. Harrison was previously employed as a Non-Executive Deputy Chairman by Heartware Pty Ltd., a Chairman by Tokai Pharmaceuticals, Inc., a Chairman by Cure Forward Corp., a Deputy Chairman by HeartWare International LLC, a Vice Chairman by New York Studio School of Drawing Painting & Sculpture, a General Partner by Oak Investment Partners, and a Venture Partner by Sevin Rosen Bayless Management Co. He also served on the board at International Partnership for Microbicides, Aileron Therapeutics, Inc., Avalo Therapeutics, Inc., CleanSlate Centers, Inc., Corvidia Therapeutics, Inc., Eledon Pharmaceuticals, Inc., The Rockefeller Foundation and Tusker Medical, Inc. He received his undergraduate degree from Princeton University, an MBA from The Trustees of Columbia University in The City of New York and a doctorate degree from The Trustees of Columbia University in The City of New York. |
| Stephen J. Tulipano |
Mr. Stephen J. Tulipano is a Chief Financial Officer at Stoke Therapeutics, Inc., a Member at Massachusetts Society of Certified Public Accountants, Inc. and a Member at The American Institute of Certified Public Accountants. Mr. Tulipano was previously employed as a Chief Financial Officer & Treasurer by Aldeyra Therapeutics, Inc., a Chief Financial Officer & Secretary by Javelin Pharmaceuticals, Inc., a Director-Corporate Accounting by Biogen Idec, Inc., and a Manager-External Reporting by Digital Equipment Corp. He received his undergraduate degree from Salem State University and an MBA from Sawyer Business School. |
| Adrian R. Krainer |
Dr. Adrian R. Krainer is an Independent Director at Stoke Therapeutics, Inc., a Deputy Director-Research at Cold Spring Harbor Laboratory, Inc., a Member at American Academy of Arts & Sciences, a Member at National Academy of Inventors, a Member at National Academy of Medicine (United States), a Member at National Academy of Sciences and a Professor at St Giles Foundation. He is on the Board of Directors at Stoke Therapeutics, Inc. He received his undergraduate degree from The Trustees of Columbia University in The City of New York and a doctorate degree from Harvard University. |
| Arthur O. Tzianabos |
Dr. Arthur O. Tzianabos is a Venture Partner at 5AM Venture Management LLC, an Independent Director at Stoke Therapeutics, Inc. and a Member-Development Board at University of New Hampshire. He is on the Board of Directors at Alliance for Regenerative Medicine, Stoke Therapeutics, Inc., Oxford Biomedica Solutions LLC and Q32 Bio, Inc. Dr. Tzianabos was previously employed as a Chairman by Akouos, Inc., a Chairman by Homology Medicines, Inc., a President & Chief Scientific Officer by OvaScience, Inc., a Senior VP, Head-Research & Early Development by Shire Plc, an Associate Professor & Member by Harvard Medical School, and a Senior VP, Head-Research & Early Development by Shire Pharmaceuticals, Inc. He also served on the board at BIND Therapeutics, Inc. and ArmaGen, Inc. He received his undergraduate degree from Boston College and a doctorate degree from the University of New Hampshire. |
| Jennifer C. Burstein |
Ms. Jennifer C. Burstein is a Senior Vice President-Finance Operations at Treeline Biosciences, Inc. and an Independent Director at Stoke Therapeutics, Inc. She is on the Board of Directors at Stoke Therapeutics, Inc. Ms. Burstein was previously employed as a Senior Vice President-Finance by Loxo Oncology, Inc., a Vice President-Finance by Acorda Therapeutics, Inc., and a Senior Director-Accounting by Oldtech, Inc. She received her undergraduate degree from State University of New York at Buffalo and an MBA from State University of New York at Buffalo. |
| Julie Anne Smith |
Ms. Julie A. Smith is a Chief Executive Officer & Director at Nuvig Therapeutics, Inc., an Independent Director at Stoke Therapeutics, Inc. and an Independent Director at Exelixis, Inc. She is on the Board of Directors at Nuvig Therapeutics, Inc., Stoke Therapeutics, Inc. and Exelixis, Inc. Ms. Smith was previously employed as a President, Chief Executive Officer & Director by ESCAPE Bio, Inc., a President, Chief Executive Officer & Director by Nuredis, Inc., an Independent Director by Audentes Therapeutics, Inc., a President & Chief Executive Officer by Raptor Pharmaceuticals, Inc., a President & Chief Executive Officer by Horizon Pharmaceutical LLC, a Chief Commercial Officer & Vice President by Enobia Pharma, Inc., a Vice President-Commercial by Jazz Pharmaceuticals, Inc., a Vice President-Global Marketing by Genzyme General, a Head-Operations & Business Development by Novazyme Pharmaceuticals, Inc., a Product Manager by Bristol Myers Squibb Co., and a Director-Health & Emerging Companies Sections by Biotechnology Innovation Organization. She received her undergraduate degree from Cornell University. |
| Garry E. Menzel |
Garry E. Menzel is currently the Director at Epilepsy Therapy Project. He also holds current positions as an Independent Non-Executive Director at Adaptimmune Therapeutics Plc, an Independent Director at Stoke Therapeutics, Inc., an Independent Director at Black Diamond Therapeutics, Inc., a Member-National Board at Epilepsy Foundation, the Principal at Royal College of Art, and an Operating Partner at GHO Capital Partners LLP. In his former roles, Dr. Menzel served as the President, Chief Executive Officer & Director at TCR2 Therapeutics, Inc. from 2016 to 2023. He was also a Managing Director at Credit Suisse Group AG from 2004 to 2008 and at The Goldman Sachs Group, Inc. from 1994 to 2004. Additionally, he held positions as the Chief Financial Officer at DaVita, Inc. from 2013 to 2015, the Chief Operating Officer at Regulus Therapeutics, Inc. from 2008 to 2013, and the Chief Strategy Officer at Axcella Health, Inc. from 2015 to 2016. He has also worked as a Research Assistant at Smithkline Beecham Plc and as a Consultant at Bain & Co., Inc.Dr. Menzel's education includes an undergraduate degree from Imperial College London in 1985, a doctorate from the University of Cambridge, and an MBA from Stanford Graduate School of Business in 1994. |
| Ian Frederick Smith |
Mr. Ian F. Smith, CPA, is an Independent Director at Stoke Therapeutics, Inc., an Executive Chairman at Solid Biosciences, Inc., a Member at Institute of Chartered Accountants in England & Wales, a Member at The American Institute of Certified Public Accountants, a Member at The Financial Executives Institute and a Senior Advisor at Bain Capital Life Sciences LP. He is on the Board of Directors at Stoke Therapeutics, Inc., Foghorn Therapeutics, Inc., Vertex Pharmaceuticals (U.K.) Ltd., Alkeus Pharmaceuticals, Inc., iVexSol, Inc. and Vertex Pharmaceuticals (Canada), Inc. Mr. Smith was previously employed as an Executive Chairman by ViaCyte, Inc., an Independent Director by Ophthotech Corp., an Independent Director by Infinity Pharmaceuticals, Inc., an Independent Director by Acorda Therapeutics, Inc., an EVP, Chief Operating & Financial Officer by Vertex Pharmaceuticals, Inc., a Partner-Life Science & Technology Practice Group by Ernst & Young LLP, and a Co-Managing Director by Vertex Pharmaceuticals (Germany) GmbH. He also served on the board at Vertex Pharmaceuticals (Europe) Ltd., EPIX Pharmaceuticals, Inc., Predix Pharmaceuticals, Inc., Tolerx, Inc. and Aavantibio, Inc. He received his undergraduate degree from Manchester Metropolitan University. |
| Arthur A. Levin |
Dr. Arthur A. Levin is an Independent Director at Stoke Therapeutics, Inc. and a Director & Strategic Leader at Avidity Biosciences, Inc. He is on the Board of Directors at Stoke Therapeutics, Inc., Avidity Biosciences, Inc. and Amylon Therapeutics BV. Dr. Levin was previously employed as an Executive Vice President-Research & Development by 358th Shelf Corp., a Senior Vice President-Development by Ionis Pharmaceuticals, Inc., a Research Leader by Hoffmann-La Roche, Inc., and a Chief Development Officer & Vice President by Roche Innovation Center Copenhagen A/S. He also served on the board at Oligonucleotide Therapeutics Society, Inc. He received his undergraduate degree from Muhlenberg College and a doctorate degree from Rochester Christian University. |
